First Meeting of BRIC-Research Advisory Board (BRIC-RAB)

1. At a Glance

2. Why in the News

3. Background & Evolution

4. Core Static Facts

5. Multi-Dimensional Analysis

Scientific / Technological - Pools fragmented institutional capacities into a single decentralized national biotech lab, easing shared infrastructure access (cryo-EM, genomics, BSL facilities) [S1]. - Supports the BioE3 Policy thrust on biomanufacturing & bioeconomy under DBT [S3].

Administrative / Governance - Replaces 14 separate governance silos with one apex society + RAB mechanism while "preserving institutional autonomy" [S1]. - RAB acts as a review-cum-mission-design body — distinct from the BRIC Governing Body and Society [S1].

Economic - Aligns with India's stated goal of a USD 300 bn bioeconomy by 2030 (Bio-vision articulated by MoST) [S2]. - Industry-academia linkages strengthened via lean Secretariat coordinating with R&D and industry [S2].

Ethical / Strategic - Centralised oversight raises questions of academic autonomy vs. mission-mode direction; RAB chairperson's stature (ex-PSA) signals technocratic legitimacy [S1]. - Strategic autonomy in vaccines, gene therapy, agri-biotech — BRIC-inStem already delivered gene therapy for Haemophilia trial breakthroughs [S4].

6. Recent Developments (last 12-18 months)

7. Prelims Hooks

8. Mains Relevance

9. Related Topics to Study Next

10. Common Errors / Trap Areas

11. Sources